UNSPSC 51283908: Sulfadiazine

This classification denotes a sulfonamide anti-infective agent with the molecular formula C10H10N4O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0N7609K889, chemically known as trisulfapyrimidine, oral suspension but generally known as sulfadiazine, which bears US NIH Compound Identifier 5215. European Medicines Agency schedules Sulfadiazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10695MIG.

UNSPSC 51283908 Sulfadiazine, a Commodity code, shows minimal recent state and local procurement activity aligned with its scope. The two opportunities in the most-recent block involve pharmaceutical procurements — one for antibiotic tablets (Doxycycline Hyclate and Ciprofloxacin Hydrochloride) and one for Naloxone and drug deactivation systems — neither of which directly solicits sulfadiazine. State and local health departments and county health authorities are the primary buyers posting under pharmaceutical UNSPSC codes, typically sourcing routine pharmaceuticals and medical supplies through piggyback cooperative purchasing agreements (like MMCAP Infuse) or competitive sealed bidding processes. The work involves warehouse-level pharmaceutical supply and quarterly distribution to county health facilities.

Recent activity appears concentrated in Florida and Illinois, with no additional states represented in the current opportunities block. The Illinois Department of Public Health completed a $2,999,999.11 piggyback pharmaceutical warehouse contract awarded to Chartwell Rx LLC on August 28, 2026, through MMCAP Infuse under an IFB process; Seminole County, Florida released an IFB (IFB60459723LAS) on June 30, 2026, for annual procurement of Naloxone and drug deactivation systems with quarterly deliveries, due July 26, 2023 (note: the listed due date appears to reference prior-year activity). The code itself does not show current, active solicitations specifically for sulfadiazine; the opportunities posted under the code reflect broader pharmaceutical commodity buying, not sulfadiazine-specific demand.